Figures & data
Table 1 Baseline demographic, therapeutic and clinical characteristics of patients enrolled in the study
Figure 2 Persistence with biologic therapy: adalimumab, etanercept and infliximab.
Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
![Figure 2 Persistence with biologic therapy: adalimumab, etanercept and infliximab.](/cms/asset/38beacf4-c442-41b9-b24e-d1d1a20a4a23/dceo_a_108730_f0002_b.jpg)
Figure 3 Percentage of patients switching from initial therapy.
Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
![Figure 3 Percentage of patients switching from initial therapy.](/cms/asset/bd94a70b-1338-4412-900f-648757ea358b/dceo_a_108730_f0003_b.jpg)
Figure 4 Percentage of patients with drug consumption escalation.
![Figure 4 Percentage of patients with drug consumption escalation.](/cms/asset/110b21f2-edd7-4489-8273-61c0adfeb048/dceo_a_108730_f0004_b.jpg)
Figure 5 Percentage of patients with drug consumption reduction.
![Figure 5 Percentage of patients with drug consumption reduction.](/cms/asset/0a54de42-02cc-482b-a85f-f9e46139ecd3/dceo_a_108730_f0005_b.jpg)
Table 2 Multivariable logistic regression model of persistence to therapy and switching among biologic agents
Figure 6 Costs for the three biologics investigated*.
![Figure 6 Costs for the three biologics investigated*.](/cms/asset/7476fb78-be18-4831-a8e2-355d1d5ad5e4/dceo_a_108730_f0006_b.jpg)
Table 3 Mean annual costs of treatment per indicator of pharmacological consumption.
Table 4 Cost of illness, generalized linear model